SG11201605256YA - Method for purifying antibody having low isoelectric point - Google Patents

Method for purifying antibody having low isoelectric point

Info

Publication number
SG11201605256YA
SG11201605256YA SG11201605256YA SG11201605256YA SG11201605256YA SG 11201605256Y A SG11201605256Y A SG 11201605256YA SG 11201605256Y A SG11201605256Y A SG 11201605256YA SG 11201605256Y A SG11201605256Y A SG 11201605256YA SG 11201605256Y A SG11201605256Y A SG 11201605256YA
Authority
SG
Singapore
Prior art keywords
isoelectric point
purifying antibody
low isoelectric
purifying
antibody
Prior art date
Application number
SG11201605256YA
Other languages
English (en)
Inventor
Yasufumi Ueda
Shohei Kobayashi
Satoko Yanagita
Takuo Kawase
Masahiro Fukunaga
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG11201605256YA publication Critical patent/SG11201605256YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201605256YA 2013-12-27 2014-12-26 Method for purifying antibody having low isoelectric point SG11201605256YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013271613 2013-12-27
PCT/JP2014/084671 WO2015099165A1 (ja) 2013-12-27 2014-12-26 等電点の低い抗体の精製方法

Publications (1)

Publication Number Publication Date
SG11201605256YA true SG11201605256YA (en) 2016-08-30

Family

ID=53479003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605256YA SG11201605256YA (en) 2013-12-27 2014-12-26 Method for purifying antibody having low isoelectric point

Country Status (16)

Country Link
US (1) US10654933B2 (zh)
EP (1) EP3088411A4 (zh)
JP (1) JP6722455B2 (zh)
KR (1) KR102344170B1 (zh)
CN (1) CN106029682B (zh)
AU (1) AU2014370873B2 (zh)
BR (1) BR112016014824A2 (zh)
CA (2) CA3233584A1 (zh)
IL (3) IL296754A (zh)
MX (2) MX2016008498A (zh)
MY (1) MY181081A (zh)
NZ (1) NZ722057A (zh)
RU (1) RU2714967C2 (zh)
SG (1) SG11201605256YA (zh)
TW (2) TWI715524B (zh)
WO (1) WO2015099165A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6823596B2 (ja) * 2015-07-31 2021-02-03 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
GEP20237513B (en) 2016-12-23 2023-06-12 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
AU2018218557B9 (en) * 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
WO2019122054A1 (en) * 2017-12-22 2019-06-27 F. Hoffmann-La Roche Ag Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4891312A (en) * 1986-08-13 1990-01-02 Monsanto Company Monoclonal antibody specific for human colon fibroblast-derived t-PA
JPS63149900A (ja) 1986-12-15 1988-06-22 Toshiba Corp 半導体メモリ
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
JPH08510116A (ja) * 1993-04-09 1996-10-29 カイロン コーポレイション 二重特異性抗原結合分子
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU744146B2 (en) 1996-09-26 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
BR9909382A (pt) 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
AU1091702A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
PL1678208T3 (pl) 2003-10-27 2013-09-30 Wyeth Llc Usuwanie agregatów o wysokiej masie cząsteczkowej z użyciem chromatografii na hydroksyapatycie
US20080058507A1 (en) 2004-02-11 2008-03-06 Hui Liu Method For The Removal Of Aggregate Proteins From Recombinant Samples Using Ion Exchange Chromatography
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2188306B1 (en) * 2007-08-10 2016-06-29 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
KR101840994B1 (ko) 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
DK2321352T3 (en) * 2008-07-18 2016-04-04 Bristol Myers Squibb Co Monovalent compositions for CD28 binding, and methods for their use
JP2010041761A (ja) * 2008-07-31 2010-02-18 Thk Co Ltd リニアモータ
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
KR101468271B1 (ko) 2009-03-19 2014-12-03 추가이 세이야쿠 가부시키가이샤 개량된 항체분자를 함유하는 의약 제제
JP5721204B2 (ja) * 2009-04-09 2015-05-20 旭化成ケミカルズ株式会社 アニオン交換基が固定された多孔膜を用いた抗体モノマーの精製方法
NZ724971A (en) * 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
US20130336972A1 (en) * 2010-08-26 2013-12-19 Christian Klein Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
US9238690B2 (en) * 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
ES2696548T3 (es) * 2010-11-19 2019-01-16 Morphosys Ag Una colección de secuencias de anticuerpos y su uso
EP2694146B1 (en) * 2011-04-05 2017-11-15 ResMed Limited Respiratory breathing apparatus
WO2013012022A1 (ja) * 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
IL267585B (en) * 2011-12-22 2022-09-01 Genentech Inc Ion exchange membrane chromatography
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient

Also Published As

Publication number Publication date
US10654933B2 (en) 2020-05-19
CN106029682A (zh) 2016-10-12
EP3088411A4 (en) 2018-12-19
US20160326253A1 (en) 2016-11-10
IL246367A0 (en) 2016-08-31
IL288023A (en) 2022-01-01
TW202026304A (zh) 2020-07-16
CA2935143A1 (en) 2015-07-02
TWI787590B (zh) 2022-12-21
MX2021004404A (es) 2021-06-15
JP6722455B2 (ja) 2020-07-15
NZ722057A (en) 2022-10-28
TW201609790A (zh) 2016-03-16
IL296754A (en) 2022-11-01
CA2935143C (en) 2024-05-07
KR102344170B1 (ko) 2021-12-27
MY181081A (en) 2020-12-17
CN106029682B (zh) 2021-04-13
AU2014370873A1 (en) 2016-07-14
RU2714967C2 (ru) 2020-02-21
KR20160102283A (ko) 2016-08-29
WO2015099165A1 (ja) 2015-07-02
CA3233584A1 (en) 2015-07-02
EP3088411A1 (en) 2016-11-02
JPWO2015099165A1 (ja) 2017-03-23
TWI715524B (zh) 2021-01-11
RU2016130664A (ru) 2018-02-01
RU2016130664A3 (zh) 2018-11-14
MX2016008498A (es) 2016-10-07
AU2014370873B2 (en) 2020-06-11
BR112016014824A2 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
PT3004163T (pt) Método para purificação de anticorpo
IL288023A (en) A method for isolating an antibody with a low isoelectric point
IL240753A0 (en) Antibody purification methods
SG11201505198WA (en) Protein purification methods
SG11201505204VA (en) Protein purification process
EP2987801A4 (en) PROCESS FOR PURIFYING ANTIBODY PROTEIN
EP3067367A4 (en) Method for purifying recombinant protein
IL268868B (en) A new method for protein purification
EP2985275A4 (en) PROCESS FOR PURIFYING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID
IL239689A0 (en) A method for producing antibodies
HK1218893A1 (zh) 蛋白質的生產方法
EP2891626A4 (en) PROCESS FOR PURIFYING DIFLUOROPHOSPHATE
GB201318039D0 (en) Engine system
HK1223684A1 (zh) 改進抗體穩定性的方法
EP3023403A4 (en) Method for purifying 2-fluorobutane
IL241779A0 (en) Method for protein production
PL2823875T3 (pl) Sposób oczyszczania spalin
EP3015473A4 (en) Method for purifying oligosaccharide peptide
EP2860259A4 (en) PROCESS FOR PRODUCING PROTEIN BY PRECIPITATION
EP2993166A4 (en) PROCESS FOR PURIFYING DIMETHYL SULFOXIDE
GB201315532D0 (en) Methods for detecting proteins
EP2982759A4 (en) PROCESS FOR CLEANING CHINOLIC ACID
GB201301384D0 (en) Method for antibody production
HK1217208A1 (zh) 提純聚酯的新方法
TWI562827B (en) Method for making adsorbent